Crowdonomics
All companies
PDX BIOTECH logo

PDX BIOTECH

Operating

PDX BIOTECH LLC

Biotech · Biotech · Louisville, KY · Founded 2019

Rapid test for periodontal disease

Post-money valuation ⓘ
$32.2M
As of Dec 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$143,716
Across 1 round since 2022
Latest share price
$20.00
Reg CF · Common Stock · Aug 2022 offering price

Financials

FY2020–FY2022 · from SEC filings · hover any figure for its source
$32K
−$768
2020
$37K
−$16K
2021
$104K
−$300K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed*
FY2021 reviewed*
FY2022
Income statement
Revenue
$31,675
$37,000
$104,000
Cost of goods sold
$16,934
$19,999
$60,000
Gross margin
47%
46%
42%
Net income
-$768
-$16,487
-$300,000
Taxes paid
$0
$0
$0
Balance sheet
Cash
$45
$3,103
$54,000
Accounts receivable
$0
$0
$0
Total assets
$4,081
$6,630
$208,000
Short-term debt
$0
$0
$27,000
Long-term debt
$0
$0
$0
Total liabilities
$0
$0
$27,000
Other
Headcount
—
10
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$32.1M
pre-money
Reg CF · Common · Aug 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Share counts as of Dec 31, 2022
ClassOutstandingVotes / shareShare of totalLast price
M Units10,544—100.0%$20.00Aug 2022

Shares outstanding over timein today's share terms

200K100K0
Jan 2022Dec 2022
M UnitsRound opened

Principal holders% as the filing states it, Apr 25, 2023

  • VYSKOS LLC50.0%of company
  • Outrider Technologies20.0%of company
  • Reggie Gresham20.0%of company
  • Everyone else (not named in filings)10.0%

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $143.7K / $1.1MInvestors 35Post-money $32.2M

Team

10 people
David McClure, Ph.D.
Founder

David McClure started PDX BIOTECH because he believed in OraStripdx and wanted to see it in the hands of veterinary teams everywhere for the good of veterinary patients. David has worked in the veterinary healthcare products industry since 2006, and in the life sciences industry since 1997, having held positions such as Chief Patent Counsel, Chief Scientific Officer, Director of Regulatory Affairs, and CEO. David is co-inventor on two of PDX's patents and was involved in drafting all the patents in the PDX portfolio. A biochemist by training, David has worked on thiol biochemistry since 1987 and is co-author of the peer-reviewed publications providing the clinical and economic validation of OraStripdx. David holds degrees from Harvard College, the University of Kentucky, the University of Louisville, and the University of North Texas, and since 1998 has been registered to practice before the U.S. Patent Office.

Tony Burgess-Cassler, Ph.D.
Co-Founder, Head of R&D and Manufacturing

Tony Burgess-Cassler, Ph.D., Head of R&D and Manufacturing, has 35 years of successful biotechnology and diagnostics experience, including over a decade in animal health. After earning his doctorate in biochemistry from the University of Illinois, Tony did postdoctoral research at the University of Wisconsin and then worked as a researcher for the U.S. Department of Agriculture. Entering the diagnostics industry, he was an inventor of the first human saliva test for HIV and was lead developer of OraStripdx, having been with PDX BIOTECH since the very beginning. Tony gives back by addressing issues of food insecurity, driving deliveries for the local Food Bank. Tony is co-author on two peer-reviewed published clinical studies validating the OraStripdx technology.

Reggie Gresham
Partner, Chief Marketing Officer

Reggie Gresham brings over 30 years of successful business experience to PDX BIOTECH. Reggie has led sales and marketing teams in the IT and digital transformation solutions markets. He has served as both Vice President and President of sales organizations supporting revenues in excess of $60 million. Capping off this successful career as an IT sales executive, Reggie joined the PDX team in 2021 to head up sales and marketing and as a cash investor. Reggie gives back by mentoring at-risk youth, providing them an accessible positive role-model, and through an organizational leadership role in 100 Black Men.

John Beran
Partner, Head of Strategy and Execution

John Beran is a CPA and MBA who brings 35 years of business experience to PDX BIOTECH. After a successful career in public accounting and healthcare finance, serving in multiple C-Suite roles including Executive, Financial and Strategy officer positions, John became an entrepreneur, founding a semiconductor company and delivering 25x return for its equity investors. John joined the PDX team in 2021, knowing his past leadership with drug development and medical device companies would benefit the organization. John gives back through leadership-advocacy in organizations addressing community housing and behavioral health needs.

Ben McBrayer
Digital Marketing Director

Ben is a rock star in the area of social media marketing and started his own shop after driving digital growth at Big Ass Fans, where he chartered a long chain of double-digit year-over-year growth through digital campaigns for the direct-to-customer channel.

Dr. Brook Niemiec
Key Opinion Leader, Clinical Advisor

Brook Niemiec DVM, FAVD, DAVDC, DEVD is a Clinical Advisor to PDX BIOTECH. As first author of the 2020 World Small Animal Veterinary Association Global Dental Guidelines, and board-certified in veterinary dentistry in both Europe and the US, Dr. Brook Niemiec is recognized as a global leader in veterinary dentistry. Dr. Niemiec is past president of the Academy of Veterinary Dentistry (AVD) as well as the AVD representative to the World Small Animal Veterinary Association.

Dr. Jan Bellows
Key Opinion Leader, Clinical Advisor

Jan Bellows DVM, FAVD, DAVDC, DABVP is a Clinical Advisor to PDX BIOTECH. As president of the Veterinary Dental Foundation and past president of the American Veterinary Dental College, Dr. Jan Bellows is an unparalleled leader among veterinary dentists. Dr. Bellows is first author of the current (2019) American Animal Hospital Association (AAHA) Dental Care Guidelines for Dogs and Cats.

Dr. Wendy Hauser
Veterinary Consultant

Dr. Wendy Hauser is an experienced animal health industry executive, with 30+ years of experience in the veterinary profession including hospital ownership, as a clinical veterinarian and in positions in the animal health industry as a pet health insurance executive and technical services veterinarian. Dr. Hauser is passionate about education and innovation, and enjoys consulting with both industry partners and individual veterinary hospitals. A regular presenter at veterinary conferences, you can find Dr. Hauser facilitating workshops on hospital culture, associate development, leadership, client relations and operations. Frequently published, she is the co-author of “The Veterinarian’s Guide to Healthy Pet Plans.” Dr. Hauser's strengths include strategic insight and guidance on business development, key stakeholder relationships and business development.

Kara Burns MS, MEd, LVT, VTS (Nutrition), VTS-H (Internal Medicine, Dentistry)
Chie Veterinary Nurse

Kara Burns MS, MEd, LVT, VTS (Nutrition), VTS-H (Internal Medicine, Dentistry) is a Clinical Advisor to PDX BIOTECH. Kara is a thought leader in veterinary nutrition and dentistry and is a prime mover in empowering veterinary nurses and veterinary technicians to take initiatives to enable their teams to deliver ever-improving care for patients. Kara is Editor in Chief of Today’s Veterinary Nurse, the official veterinary nursing journal of the North American Veterinary Community (NAVC), and Director of Veterinary Nursing Development at WellHaven Pet Health.

Show 1 more person
Mary Berg BS, RVT, RLATG, VTS (Dentistry)
Key Opinion Leader, Clinical Advisor

Mary Berg BS, RVT, RLATG, VTS (Dentistry) is a Clinical Advisor to PDX BIOTECH. Mary Berg is the most sought-after veterinary dental technician specialist in the US and is second author of the 2019 AAHA Dental Care Guidelines for Dogs and Cats. Mary is president of Beyond the Crown Veterinary Education, providing on-site and remote accredited continuing education to veterinary practices seeking to strengthen their dentistry programs.

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 4 annual reports (FY2022–FY2025)

35 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRMay 28, 20240001941155-24-000004
    EDGAR
  • Form C-ARApr 25, 20230001665160-23-000761
    EDGAR
  • Form C-UDec 20, 20220001665160-22-003096
    EDGAR
  • Form C/ANov 8, 20220001665160-22-002893
    EDGAR
  • Form CAug 12, 20220001665160-22-002201
    EDGAR
Source: ManualCIK 0001941155KYShare price $20.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.